Literature DB >> 32265306

Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis.

Nicola Adderley1, Christopher J Humphreys2, Hayley Barnes3,4, Brett Ley4, Zahra A Premji5, Kerri A Johannson6,7.   

Abstract

BACKGROUND: The role of bronchoalveolar lavage fluid (BALF) lymphocyte percentage in diagnosing chronic hypersensitivity pneumonitis (CHP) is unclear. We conducted a systematic review and meta-analysis of bronchoalveolar lavage (BAL) lymphocyte percentage in the diagnosis of CHP.
METHODS: We searched Medline, Embase and the Cochrane Library from inception to August 2019. Individual patient data were obtained to test performance characteristics of BAL lymphocyte percentage at different thresholds. Random-effects models were used for pooled estimates, with comparisons made between CHP and non-CHP interstitial lung diseases (ILDs).
RESULTS: Fifty-three studies were included in the systematic review and 42 in the meta-analysis. The pooled estimate for BAL lymphocyte percentage was 42.8% (95% CI 37.7-47.8, I2=95.3%) in CHP, 10.0% (95% CI 6.9-13.1, I2=91.2%) in idiopathic pulmonary fibrosis (IPF), 23.1% (95% CI 3.0-43.2, I2=85.2%) in non-IPF idiopathic interstitial pneumonia (IIP), 23.4% (95% CI 11.0-35.9, I2=45.7%) in connective-tissue disease associated ILD (CTD-ILD) and 31.2% (95% CI 17.6-44.8, I2=95.2%) in sarcoidosis. Results differed between CHP and IPF (p<0.0001), non-IPF IIP (p=0.0309) or CTD-ILD (p=0.0824), but not between CHP and sarcoidosis (p=0.0966). Using individual patient data from eight studies, a lymphocyte percentage threshold of >20% provided a sensitivity of 68.1% and a specificity of 64.8% for CHP. Higher thresholds provided lower sensitivity with higher specificity. Older age and ever having smoked were associated with lower lymphocyte percentage in CHP.
CONCLUSIONS: BAL lymphocyte percentage is higher in CHP compared to IPF and other IIPs, with higher thresholds providing improved specificity at the cost of sensitivity. However, the parent studies are at risk of incorporation bias and prospective studies should evaluate the additive discriminate value of BAL lymphocyte percentage to accurately diagnose CHP.
Copyright ©ERS 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32265306     DOI: 10.1183/13993003.00206-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Hypersensitivity pneumonitis.

Authors:  Ulrich Costabel; Yasunari Miyazaki; Annie Pardo; Dirk Koschel; Francesco Bonella; Paolo Spagnolo; Josune Guzman; Christopher J Ryerson; Moises Selman
Journal:  Nat Rev Dis Primers       Date:  2020-08-06       Impact factor: 52.329

2.  Propionibacterium acnes-associated sarcoidosis complicated by acute bird-related hypersensitivity pneumonitis.

Authors:  Michiru Sawahata; Noritaka Sakamoto; Hideaki Yamasawa; Yuki Iijima; Hirotoshi Kawata; Tetsuo Yamaguchi; Keisuke Uchida; Yoshinobu Eishi; Masashi Bando; Koichi Hagiwara
Journal:  BMC Pulm Med       Date:  2020-11-07       Impact factor: 3.317

3.  Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A case-control study.

Authors:  Sabina A Guler; Eva Wohlfarth; Sabina Berezowska; Thomas K Geiser; Lukas Ebner; Manuela Funke-Chambour
Journal:  Respir Res       Date:  2021-04-23

4.  Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States.

Authors:  Kerri I Aronson; Ronan O'Beirne; Fernando J Martinez; Monika M Safford
Journal:  Respir Res       Date:  2021-08-10

5.  Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis.

Authors:  Junyi Wang; Lei Zhang; Li Luo; Ping He; Anying Xiong; Manling Jiang; Yao Liu; Shengbin Liu; Qin Ran; Dehong Wu; Ying Xiong; Xiang He; Guoping Li
Journal:  Cell Death Discov       Date:  2022-01-28

6.  The Prognostic Value of Integrated Analysis of Inflammation and Hypoxia-Related Genes in Idiopathic Pulmonary Fibrosis.

Authors:  Jun Liu; Liming Gu; Wenli Li
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

7.  Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis.

Authors:  Yasushi Horimasu; Kakuhiro Yamaguchi; Shinjiro Sakamoto; Takeshi Masuda; Shintaro Miyamoto; Taku Nakashima; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori
Journal:  Orphanet J Rare Dis       Date:  2021-07-03       Impact factor: 4.123

Review 8.  Challenges in the Diagnosis and Management of Fibrotic Hypersensitivity Pneumonitis: A Practical Review of Current Approaches.

Authors:  Teng Moua; Tananchai Petnak; Antonios Charokopos; Misbah Baqir; Jay H Ryu
Journal:  J Clin Med       Date:  2022-03-08       Impact factor: 4.241

Review 9.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10

Review 10.  A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.

Authors:  Christopher J Ryerson; Tamera J Corte; Jeffrey L Myers; Simon L F Walsh; Sabina A Guler
Journal:  Eur Respir J       Date:  2021-12-16       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.